B2M and Dravet syndrome: This research suggests targeting peripheral B2M as a potential strategy for treating cognitive impairment in individuals with AD and DS, potentially overcoming the challenge of drug delivery across the BBB that is commonly encountered in the treatment of central nervous system (CNS) diseases.